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Abstract: 
Recurrence of prostate cancer after initial treatment with radiation therapy is highly dependent on pre-
treatment risk group and unfortunately, a proportion of patients fail primary treatment. The treatment of 
recurrence after primary radiation is rapidly changing with advances in imaging and it is important to 
distinguish those with a local failure from those with distant failure. If disease remains locally confined, 
salvage treatment with a variety of techniques can still provide a potential cure. Patients with distant 
failure are often treated with androgen deprivation, or in those with a shorter life expectancy, conservative 
management. In patients with a higher burden of metastatic disease, there is emerging evidence that 
chemotherapy and advanced androgen therapy can improve survival. We review the relevant literature on 
available salvage treatment options and appropriate patient selection for patients with recurrent prostate 
cancer after radiation therapy. We report on the efficacy and adverse effects of the currently available 
local salvage modalities including salvage radical prostatectomy, high dose rate and low dose rate 
brachytherapy, cryotherapy, high intensity focused ultrasound, and stereotactic body radiation therapy. 
We additionally discuss diagnosis of oligometastatic disease on imaging and current approaches to 
treatment with either radiation or surgery. While a full review of chemotherapy and advanced androgen 
therapies is beyond the scope of this article we briefly discuss their use in the treatment of newly 
diagnosed recurrence after radiation. 
1. Introduction 
Prostate cancer is the most commonly diagnosed non-dermatologic cancer in men in developed countries 
and has the second highest incidence to lung cancer among males globally.1 Definitive treatment of 
disease confined to the prostate most commonly involves surgery, radiation therapy (RT) or a 
combination of both and patients over the age of 65 are more likely to receive radiation therapy than 
surgery.2,3  
Failure of primary treatment is separated into biochemical failure and clinical failure. Biochemical failure 
relates to rising serum PSA after treatment, and is used to predict future clinical failure. Clinical failure is 
when a patient presents with symptoms related to local progression or distant metastasis of prostate 
cancer after treatment. Failure after primary radiation therapy is heavily influenced by pre-treatment risk 
grouping, but Nguyen et al. report that between 20% and 50% of patients may experience biochemical 
failure.4 Rising PSA often predates clinical metastatic disease by many years and a subset of those with 
biochemical failure may continue to have organ-confined disease and benefit from additional local 
treatment.5 Most patients with biochemical failure are managed with observation or androgen deprivation 
therapy (ADT) with only  a small minority receiving local salvage therapy, though local salvage therapy 
may be underutilized.6 
In this review we will discuss which patients may benefit from local salvage therapy after failure of 
primary radiation therapy, and the general management of biochemical failure after primary radiation 
therapy. We will explore the various salvage treatment modalities and compare survival and morbidity 
outcomes. 
2. Patient selection 
Failure after primary treatment is most often diagnosed as biochemical recurrence (BCR) due to rising 
serum PSA. BCR after radiation therapy is defined as a rise of ≥2 ng/mL above post-treatment nadir PSA 
value (Phoenix Definition)7. While recurrence is defined based on change in PSA, the absolute PSA value 
is associated with likelihood of recurrence and is predictive of time to metastatic disease8,9. Additionally, 
the absolute PSA at the time of salvage therapy is associated with biochemical failure free survival10. 
Among patients with biochemical recurrence in whom the site of recurrence is detected, disease isolated 
locally in the prostate gland and seminal vesicle is most common. According to a study of patients with 
clinically detectable recurrence at Memorial Sloan Kettering Cancer Center, the anatomic distribution of 
recurrence was 41.6% local, 9.7% lymphotropic, 20.3% osteotropic, and 28.5% multiorgan/visceral11.  
Patients with metastatic disease, or distant failure, are not often candidates for curative intent local 
salvage therapy, and it is therefore of particular importance to attempt to identify these patients to spare 
them the morbidity of a salvage treatment from which they may not benefit. The standard metastatic 
workup after biochemical failure has been a bone scan and cross-sectional imaging of pelvis for decades. 
However, advances in technology including positron-emission tomography (PET) with 18F-fluciclovine, 
choline C-11, or 18F sodium fluoride along with whole body MRI or CT have allowed for earlier detection 
of metastatic disease, and detection of small volume loco/regional disease recurrence.12,13 Imaging using 
radio-labelled prostate specific membrane antigen (PSMA) is an additional promising new technology to 
help identify disease14,15. Despite these more sensitive tests, many patients who undergo local salvage 
treatment will develop distant failure, some of whom presumably had undetectable micrometastasis at the 
time of salvage and would have benefited from more restrictive patient selection. Patients with higher T 
stage and Gleason score at diagnosis as well as PSA doubling time (PSA-DT) after recurrence of less than 
6 months are more likely to develop distant metastasis after attempted local salvage and may not benefit 
from local treatment.16  
The recent advances in imaging have also allowed for identification of “oligometastasis” which describes 
the state of having limited metastatic spread, often to a single lymph node or distant locus. Patients with 
oligometastases may still be considered candidates for curative treatment and benefit from focal therapy 
to the identified lesion(s).  
Patients with overt metastatic disease will not benefit from local salvage therapy, but in patients without 
evidence of metastasis the benefit of local salvage compared to ADT or observation is a controversial 
topic. Conclusions are based largely on small retrospective studies. The NCCN suggests that candidates 
for local salvage therapy are patients with original clinical stage T1-T2, Nx or N0, with life expectancy 
greater than 10 years, pre-salvage serum PSA <10 ng/mL, no evidence of distant metastasis based on 
imaging and PSA-DT, and a positive prostate biopsy.17 None of the studies discussed in this article 
included only those patients meeting all of these criteria and it is therefore important to note the differing 
inclusion criteria for each study (Table 1).  
3. Local salvage modalities 
In patients who have radiographic and/or biopsy proven disease confined to the prostate after initial 
treatment with radiation therapy, local salvage treatment provides the possibility of a cure. However, only 
a small proportion of patients who fail primary radiation therapy receive local salvage treatment and there 
is currently no consensus on a best salvage treatment modality.6 In evaluating local salvage options it is 
important to note that there are different definitions of biochemical failure, significant disparity in patient 
characteristics, and variation in the use of prior, neoadjuvant, and adjuvant ADT across the literature on 
this subject (Table 1). 
3.1 Radical Prostatectomy 
Salvage radical prostatectomy (SRP) after external beam radiation therapy (EBRT) is more technically 
difficult and is associated with higher potential for morbidity than primary radical prostatectomy (RP) due 
to effects of primary radiation on normal tissues in the pelvis. For these reasons SRP should be performed 
by an experienced physician at a high volume center and patients should also be counselled regarding the 
increased risk of side effects with this procedure. Removal of the prostate gland is achieved by open 
approach or minimally invasive robotic or laparoscopic technique. Nerve sparing techniques attempt to 
preserve erectile function by leaving the neurovascular bundles intact but are only appropriate when 
tumor control will not be compromised. Pelvic lymph node dissection is often performed at the discretion 
of the surgeon and may be especially appropriate in the setting of oligometastatic disease confined to 
pelvic lymph nodes. 
Oncologic Outcomes 
In a multi-institutional, international case series, Chade et al. reported on the treatment of 404 patient with 
SRP after initial RT. The median age was 65 years and median pre-salvage PSA was 4.5 ng/mL. At a 
median follow up of 4.4 years they reported 5 year biochemical failure free survival (bFFS) of 48%, 
metastasis free survival (MFS) of 83% and cancer specific survival (CSS) of 92%.18 These figures are 
similar to those reported by two smaller single center studies. Mandel et al. reported  5 year bFFS of 
48.7% and CSS of 88.7% while Sanderson et al. reported progression free survival (PFS), which they 
define as time to ADT initiation or progression, of 47% at 5 years.19,20 In a case series of 199 patients 
treated at the Naval Medical Center, bFFS was 58% and 48% at 5 and 10 years respectively.21 Despite 
their slightly higher bFFS, they found a slightly lower CSS of 79% and 65% at 5 and 10 years 
respectively.  
Taken as a whole, the literature for SRP suggest that in carefully selected patients with residual disease in 
the prostate, approximately half can be cured with surgery. However, it is important to note that patient 
selection for salvage is crucial, and most of the published series of SRP span many decades in which time 
radiation, surgical and imaging techniques have changed significantly. 
Adverse Effects 
As previously mentioned the morbidity of SRP can be significant. Ward et al. reported on morbidity after 
SRP, noting that 4% of SRP patients suffered operative rectal injury which increased to 10% of the 
patients who had undergone cystoprostatectomy due to radiation induced adhesions involving the rectal 
wall, bladder base, or trigone.21 In a series of patient surveys from 33 patients at a median of 7.5 years 
from SRP, Sanderson et al. reported that 73% of respondents found their overall urinary function to be 
“small,” “very small,” or “no” problem, while continence rates were higher among those who had 
received an artificial urethral sphincter.20 Not surprisingly, they found a clinically significant 
improvement in sexual function in patients with inflatable penile prosthetic implant over patients with 
nerve sparing SRP, but found no difference in sexual bother between the groups. Bladder neck 
contractures were a common complication in both studies, occurring in 22%-41% of patients.20,21 
3.2 Brachytherapy 
In patients who have previously received EBRT, brachytherapy (BT) can be an appealing option due to 
the ability to deliver a very conformal high dose to the target lesion while minimizing dose to surrounding 
healthy tissue. There is also the convenience of as few as a single treatment session. The published 
literature for salvage brachytherapy includes a patient population that was largely treated with ADT prior 
to salvage brachytherapy, and variable rates of neoadjuvant ADT between study populations results in a 
wide range of biochemical control outcomes. However, in more contemporary and less pre-treated 
populations, low dose rate or high dose rate brachytherapy appear to be able to cure about half of all local 
failures in patients who are candidates for the procedures. 
3.2.1 Low Dose Rate Brachytherapy 
Low dose rate brachytherapy (LDR BT) is performed by implanting radioactive seeds directly into and 
around the target lesion or the entire prostate gland. Seeds remain in the gland permanently and deliver 
dose slowly over many months as the isotopes decay. Frequently used radioisotopes include 125I (half-life 
59.4 days) and 103Pd (half-life 17.0 days).  
Oncologic Outcomes 
The largest reported case series of patients receiving salvage BT was published by Vargas et al. In this 
study of 69 patients, 89% of the patients received ADT neoadjuvantly and or adjuvantly and if patients 
demonstrated serum PSA > 5 ng/mL while on ADT their cancer was considered castration resistant. Their 
5-year bFFS was 73% for castration sensitive and 20% for castration resistant cancers. MFS and overall 
survival (OS) were 90% and 64% at 5 years.22 In a study of largely high risk patients, Baumann et al. 
report on reduced dose brachytherapy with concurrent ADT and found relapse free survival to be 79% 
and 67% at 5 and 7 years respectively and distance metastasis free survival was 93% and 86% at 5 and 7 
years23. Grado et al. reported on a series of 49 patients with median age 73.3 and pre-salvage PSA 5.6 
excluding patients with neoadjuvant ADT or prior orchiectomy. With median follow up of 5.3 years they 
report 5-year bFFS, CSS, and OS of 34%, 79%, and 56% respectively.24 Of these 49 patients, 11 had 
already failed one additional salvage modality and 2 had failed two previous modalities. More recently, 
Burri et al. reported on 37 patients at Mount Sinai with median age of 70 years and pre-salvage PSA of 
5.6 ng/mL. They reported a bFFS of 54%, CSS of 96% and OS of 74% at 10 years.25  
Adverse Effects 
In a phase II prospective study of 92 patients previously treated with EBRT, Crook et al. found that LDR 
BT was well tolerated, with only 14% of patients experiencing late grade 3 GI or GU adverse events and 
no reported early or late grade 4 or higher events26. Moman et al. reported the toxicity experienced by 31 
patients at 9 years median follow up and they found that 87% of their patients experienced grade 1-2 GU 
toxicity in the early phase within 90 days of treatment which decreased to 55% after 90 days.27 The 
prevalence of grade 3 GU toxicity increased from 3% to 19% from the early to the late phase. Grade 1-2 
GI toxicity occurred in 55% and 51% of patients in the early and late phase respectively. Grade 3 GI 
toxicity was rare and occurred in only 6% of patients in the late phase and no patients experienced grade 
≥ 4 GI or GU toxicity. Grado et al. reported toxicities among their 49 patients which included two cases 
of persistent gross hematuria, three patients with significant penile dysuria, and two patients with rectal 
ulcers.24 They found that acute urinary symptoms were common but typically transitory. 
3.2.2 High Dose Rate Brachytherapy 
Administration of high dose rate brachytherapy (HDR BT) involves insertion of catheters into the prostate 
guided by a perineal template. Highly radioactive isotopes such as 192Ir are inserted and moved through 
the catheters to distribute dose per the treatment plan. In some cases, patients may have the catheters 
implanted more than once and often multiple doses are delivered hours apart with a single implant. 
Oncologic Outcomes 
Chen et al. published a retrospective series of 52 patients undergoing salvage HDR BT with 36 Gy in 6 
fractions across 2 separate implants. Patients had a median age of 67.5 and median pre-salvage PSA of 
5.0 ng/mL. With median follow up of 59.6 months they found 5-year bFFS of 51% with OS of 92%.28 In 
a prospective phase II study of HDR BT in 42 patients treated with 32 Gy in 4 fractions using a single 
implant, Yamada et al. reported a 5 year bFFS of 68.5% and OS of 79%.29 This study excluded patients 
with pre-salvage PSA > 10 ng/mL and any patient with international prostate symptom score greater than 
15.  
Adverse Effects 
Yamada et al. additionally evaluated treatment toxicity in their 42 patients.29 They found acute grade 1-2 
GU toxicity in 78% of patients, and up to 96% of patients in the late phase. There were 3 total grade 3 GU 
toxicity events with no grade 4 or greater. GI toxicity was largely transient rectal bleeding without any 
grade 3 or greater events. Chen et al. reported grade ≥2 acute and late GI toxicity in 38% and 56% of 
patients respectively with only 4% of patients experiencing any grade 2 GI toxicity.28 Acute sexual 
dysfunction was found to be grade ≥2 in 19% of patients, increasing to 35% of patients for late 
dysfunction.  
3.3 Cryotherapy 
Cryotherapy, also known as cryosurgery and cryoablation therapy, involves placement of probes within 
the prostate that undergo extreme cooling using argon gas. Prostate tissue is consumed by an expanding 
ball of ice that is monitored by transrectal ultrasound often through multiple freeze-thaw cycles.30 Rapid 
freezing of the tissue results in ice crystal formation that leads to cell death.31 A urethral warming catheter 
is used to prevent urethral tissue damage. 
Oncologic Outcomes 
Wenske et al. published a series of 328 patients who received salvage cryotherapy between 1994 and 
2011 at Columbia University and had mostly received EBRT as primary treatment (49 patients had 
primary LDR BT and 20 patients had primary cryotherapy).32 The median age was 65.8 years and median 
pre-salvage PSA was 4.0 ng/mL in the study. Their bFFS was 63% and 35% at 5 and 10 years 
respectively. CSS was 91% and 79% and OS was 74% and 45% at 5 and 10 years respectively. Lu et al. 
reported their series of 187 patients with mean follow up of 7.5 years and found disease free survival 
(DFS), which included results of serum PSA and some patients who received biopsies, to be 47% at 5 
years and 39% at 10 years while MFS and OS were 87% and 95% respectively at 5 years.33 
Adverse Effects 
Long term complications of salvage cryotherapy were assessed with a survey of 112 patients at a median 
age of 68.8 years and mean follow up of 16.7 months.30,34 They found that 72% of patients reported 
incontinence, 66% reported medium to severe voiding symptoms, 63% lost potency among those who 
were potent prior to cryotherapy, and 44% reported chronic perineal pain.34 They additionally found a 
33% overall satisfaction rate with cryotherapy. A similar report by Ng et al. fund that among 187 patients 
treated with salvage cryotherapy 8% required surgery to address complications after treatment.35  
3.4 High Intensity Focused Ultrasound 
High-intensity focused ultrasound (HIFU) is used in the treatment of localized prostate cancer through the 
ablation of tissue by heat generated by a beam of focused ultrasound using a transrectal probe.36 The US 
Food and Drug Administration (FDA) approved HIFU to be marketed for use in prostate tissue ablation 
only as recently as 2015 due to lack of substantial clinical outcome data.37 There is limited data on HIFU 
outcomes relevant to patient decision making for primary treatment of prostate cancer and with this lack 
of primary treatment data, it follows that evidence in the context of local salvage therapy is even more 
sparse.  
Oncologic Outcomes 
Crouzet et al. published the largest series of 418 patients undergoing S-HIFU from 1995-2009 in an 
international, multi-institutional analysis.38 Mean patient age was 68.6 years, on average 5.1 years after 
primary treatment. Mean pre-salvage PSA was 6.8 ng/mL and median follow up was 3.3 years. Some 
patients had a history of ADT use but none continued ADT after HIFU. Most patients received one HIFU 
session, with about 13% of patients receiving two or three sessions. They reported 37% of patients were 
free from initiation of ADT at 5 years but also report a bFFS of 49% overall at 5 years. Gelet et al. 
reported 30 month actuarial disease free rate (bFFS or negative biopsy) as 38% in their series of 71 
patients with a median pre-salvage PSA of 5.7 ng/mL, and 13% of patients developed metastases.39 
Kanthabalan et al. reported a bFFS of 48% at 3 years with 92% overall survival among 150 patients.40 
Interestingly Uddin et al. biopsied a portion of their cohort of 84 patients treated with S-HIFU and found 
that 43% of those biopsied (25% of the entire cohort) demonstrated a positive biopsy after S-HIFU 
treatment.41 
Adverse Effects 
HIFU is less invasive than prostatectomy, but can still lead to significant morbidity. In an earlier study 
Crouzet et al. reported 16% of patients experienced bladder outlet obstruction. They also reported that 2% 
and 3% of patients developed a urethrorectal fistula and pubic bone osteitis respectively.42 Gelet et al. 
found that 6% of their patients developed urethrorectal fistula.39 
3.5 Stereotactic Body Radiation Therapy 
Stereotactic body radiation therapy (SBRT) is similar to EBRT except that the treatment dose is typically 
delivered in 2-5 total fractions. SBRT is an appealing non-invasive way to approximate the dosimetry 
achieved by HDR BT.43 SBRT is a relatively new technique and there are few studies investigating the 
use of SBRT for local salvage therapy in prostate cancer. 
Presenting preliminary results of their prospective study of 29 patients treated with salvage SBRT with 34 
Gy in 5 fractions, Fuller et al. reported a bFFS of 82% at 2 years. The median age was 73 and median pre-
salvage PSA was 3.1 ng/mL. They found GU toxicity of grade ≥2 in 18% of patients and no patients with 
GI toxicity above Grade 1. Of 10 patients who were sexually potent prior to SBRT, 4 reported no 
significant change while 3 experienced a major decrease in potency44. 
In another small series, Leroy et al. reported bFFS of 54% at two years among their 23 patients. Patients 
received 36 Gy in 6 fractions and had a median pre-salvage PSA of 2.5 ng/mL. They reported 26% of 
patients with GU toxicity grade ≥2 and two patients with grade 2 rectal toxicity.45 
4. Treatment of Oligometastatic Disease 
Treatment of oligometastatic disease typically consists of either radiation or surgery. Radiation therapy 
usually consists of SBRT while surgery involves salvage pelvic lymph node dissection (sPLND) when 
disease is confined to the pelvic nodes and metastasectomy for other isolated lesions. While there is 
growing interest and ongoing research investigating treatment of oligometastatic prostate cancer, 
published data remains sparse.  
Ost et al. published a phase II trial comparing surveillance to metastasis-directed therapy (MDT) with 
either SBRT or surgery.46 They found that the MDT group had a significantly longer median time to 
initiating ADT and no patients in the MDT group experienced grade 2 or greater toxicity. An Italian study 
of 40 patients evaluated the use of SBRT in patients with isolated lymph node recurrent prostate cancer.47 
They reported a two year bFFS of 44%.  
Surgery for oligometastatic disease can target distant metastases, but most commonly will target 
lymphatic disease with salvage pelvic lymph node dissection (sLND). A German study of sLND 
investigated outcomes of surgery in patients with recurrent prostate cancer with lymphatic disease 
detected on imaging.48 Most patients had received prostatectomy as primary treatment, but 10% of 
patients had received RT. Of the 69 patients included in the analysis, 27.3% demonstrated bFFS at 5 years 
and 35.1% remained free from systemic therapy at 5 years. Postoperative lymphocele occurred in 11.5% 
of patients, half of whom required surgical intervention. A study of 52 patients with recurrence after RP at 
Mayo Clinic found that sLND resulted in bFFS of 45.5%, MFS of 46.9%, and CSS of 92.5% all at 3 
years.49 This patient population was free from additional treatment in 46.2% of cases at last follow up. As 
with these studies, most evidence for sLND is in patients who underwent RP for primary treatment. 
Patients with recurrence after primary RT differ from RP patients in that they may have received previous 
radiation to their lymph nodes, and they retain their prostate gland. However, if imaging identifies disease 
isolated to the lymph nodes and surgical resection is feasible, it may be reasonable to assume similar 
outcomes in patients with recurrence after RT.  
5. Systemic management options 
In recent studies PET/CT is able to identify a lesion(s) in over 70% of patients with a PSA greater than 
0.5.14,15 However, advanced imaging is not always available, and even with advanced imaging some 
patients have only biochemical evidence of disease and are presumed to be metastatic. Patients with 
diffuse metastatic disease on imaging or other complicating factors may not be candidates for metastasis 
directed therapy, and for these reasons systemic treatment remains a common option for patients who fail 
radiation therapy. 
5.1 Androgen Deprivation Therapy 
Androgen deprivation therapy (ADT) is a staple in the treatment of metastatic prostate cancer and has 
additionally been associated with improved outcomes in localized disease.50,51 Patients treated with ADT 
experience side effects including impotence, decreased libido, hot flashes, fatigue, and weight gain among 
others. There is evidence of an association with incident diabetes, coronary artery disease, myocardial 
infarction, and sudden cardiac death with ADT.52 
The Timing of Androgen Deprivation (TOAD) trial was a randomized, non-blinded, phase III trial that 
included patients with biochemical recurrent disease without evidence of metastases (group 1) or who 
were not eligible for curative treatment (group 2) and evaluated the effect of immediate versus delayed 
initiation of ADT. Men assigned to the delayed arm were recommended to start ADT at least 2 years after 
randomization unless they developed symptoms, metastases, or a PSA doubling times of <6 months. This 
study found an improvement in OS in favor of immediate ADT, but among the group 1 patients this 
benefit did not reach statistical significance .53 The immediate ADT group had more low-grade side 
effects, but overall quality of life was similar between the groups. Given the lack of an overall survival 
benefit for immediate initiation of ADT in patients with biochemical failure, many clinicians will delay 
initiation of ADT until an arbitrary cut off (e.g. PSA of 10) or until the PSA doubling time is <6 months.  
5.1.1 Continuous vs Intermittent Androgen Deprivation Therapy 
Traditionally, ADT was administered continuously beginning at the time of biochemical recurrence, but 
due to the significant side effects of ADT there has been interest in intermittent androgen deprivation 
(IAD). IAD allows for a treatment-free period, and in theory fewer side effects. In a randomized 
controlled non-inferiority trial of 1386 patients, Crook et al. compared IAD to continuous androgen 
deprivation. IAD was given in 8 month treatment cycles followed by non-treatment until PSA was >10. 
They found that OS was not inferior in the IAD group versus the CAD group.54 The median survival was 
8.8 vs 9.1 years in the IAD and CAD groups respectively. Their study additionally found symptom-based 
quality of life outcomes to favor IAD including hot flashes, desire for sexual activity, and urinary 
symptoms. In a randomized controlled trial of 1,535 patients with metastatic disease, Hussain et al. 
similarly found fewer adverse events among the IAD group, however they were unable to conclusively 
demonstrate non-inferiority in regard to survival55. This study helps to support the paradigm of 
intermittent androgen deprivation, however it is difficult to directly apply the outcomes to our patient 
population since all of their patients had metastatic disease and a minority had been previously treated 
with radiation. 
5.2 Chemotherapy 
Recent studies have evaluated the efficacy of chemotherapy in patients with locally advanced and/or 
metastatic prostate cancer. The use of systemic therapy in the context of PSA-only recurrence without 
evidence of metastasis has been investigated, but these patients have made up a small portion of larger 
randomized trials. 
The STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug 
Efficacy) trial is evaluating various systemic therapies in local recurrent, locally advanced, and metastatic 
prostate cancer. The patient population being recruited into the STAMPEDE trial ranges from locally 
advanced (two high risk features) to metastatic, with the majority of patients having newly diagnosed 
metastatic disease without previous treatment. 
In a publication evaluating the benefit of adding docetaxel, zoledronic acid, or both to standard of care 
(ADT +/- radiation) the STAMPEDE authors randomized 2,962 patients between 2005-2013.56 Standard 
of care demonstrated a median overall survival of 71 months while addition of docetaxel resulted in a 
median overall survival of 81 months (HR 0.78; 95% CI 0.66-0.93; p=0.006). Addition of zoledronic acid 
to standard of care and to standard of care plus docetaxel did not demonstrate an advantage compared to 
standard of care plus docetaxel. Failure free survival favored the docetaxel group over standard of care 
alone (HR 0.61; 95% CI 0.53-0.70; p<0.001). However, the survival benefit in the setting of biochemical 
failure only is difficult to ascertain as only 6% of the patients in this study failed primary treatment. In 
addition the survival benefit of chemotherapy came at the added cost of treatment toxicity with a 20% 
increase in grade 3-5 toxicity (32% vs 52%). 
In a separate cohort of 1917 patients, the STAMPEDE authors investigated the effect of ADT alone 
versus ADT plus abiraterone and prednisolone. Failure free survival was 75% in the combination therapy 
group versus 45% in the ADT alone group (HR 0.29; 95% CI 0.25-0.34; p<0.001). Patients who received 
combination therapy experienced fewer symptomatic skeletal events than those who received ADT alone 
(HR 0.46; 95% CI 0.37-0.58; p<0.001), but again patients in the combination group were more likely to 
experience grade 3 or higher toxicity (47% vs 33%). 57 Again in this cohort only 5% of patients had been 
previously treated.  
For patients with clinical or radiographic evidence of metastatic disease the CHAARTED trial 
randomized 790 patients with metastatic, hormone sensitive prostate cancer to receive ADT alone or ADT 
plus docetaxel.58 There was an overall survival benefit with the addition of docetaxel over ADT alone 
(HR 0.61; 95% CI 0.47-0.80; p<0.001). Median time to castration resistant disease was 20.2 months for 
combined therapy compared to 11.7 months with ADT alone (HR 0.61; 95% CI 0.51-0.72; p<0.001). 
However, again the proportion of patients who had failed previous primary treatment was small (72.8% 
no prior treatment, 19.5% prostatectomy, and 7.6% radiation) making extrapolation to failure after 
primary RT difficult. 
In a small phase II study of 41 patients, McKay et al. treated patients with docetaxel, bevacizumab, and 
ADT after biochemical recurrence following local therapy.59 At 1 year after completion of therapy, only 
44% remained free from biochemical recurrence and over half of their patients reinitiated ADT within 
two years due to disease progression. Additionally 39% and 12% of patients experienced grade 3 and 
grade 4 treatment-related adverse events and 22% of patients discontinued treatment due to toxicity.  
Chemotherapy and advanced hormonal therapy are moving to the forefront of treatment for metastatic 
prostate cancer, but their role in treating patients after failure of primary radiation remains controversial. 
Taken as a whole, the published randomized trials suggest that patients with a higher burden of disease 
(clinical or radiographic metastasis) are most likely to benefit from chemotherapy or advanced hormonal 
therapy after failure of primary radiation. 
5.3 Watchful Waiting 
In patients with recurrence who are elderly, have comorbid conditions, or otherwise elect to forego 
treatment, watchful waiting may be an appropriate strategy. In a retrospective study of men with PSA 
failure after radical prostatectomy the median time to development of clinical metastatic disease was 8 
years from first biochemical failure, and the median time to prostate cancer specific death was 5 years 
from development of metastatic disease.60 Clearly biochemical failure does not typically indicate 
imminent death from disease, and therefore in patients with a life expectancy <10 years aggressive 
salvage or hormonal treatment is unlikely to prevent clinical disease manifestation or death. 
6. Conclusions 
Salvage for failure after definitive RT for prostate cancer is a rapidly evolving field as newer imaging 
technologies are detecting more localized/oligometastatic disease. While there is no high quality 
comparative data to guide the decision of which local salvage therapy is best, it is reasonable to offer 
local salvage based on institutional strengths in patients with a pre-salvage PSA <10, life expectancy >10 
years, PSA doubling time of >6 months, no evidence of distant disease, and either biopsy proven or 
imaging evidence of local failure. For patients with biochemical failure and no measurable disease, ADT 
remains the backbone of treatment, and this can be given continuously or intermittently with no difference 
in OS. Chemotherapy and advanced hormonal therapy have shown a survival benefit in patients with 
metastatic disease, but the benefit is likely greatest in those with a higher burden of disease. 
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Table 1: Summary of studies evaluating salvage treatment options for prostate cancer 
Study Study type Patient 
Characteristics 
Treatment Oncologic Outcomes Toxicity Outcomes 
Salvage Radical Prostatectomy (SRP) 
Chade et al.18 
2011 
N=404 
Retrospective, 
international case 
series  
1985-2009 
 
Median age 65 
Median pre-salvage PSA 4.5 ng/mL 
Median FU 4.4 yrs 
SRP bFFS: 48% at 5 yrs, 37% at 10 yrs 
MFS: 83%  at 5 yrs, 77% at 10 yrs 
CSS: 92% at 5 yrs, 83% at 10 yrs 
Pre-SRP PSA and gleason score at SRP predicted BCR 
and metastasis and positive LNs predicted metastasis 
 
Mandel et al.19 
2016 
N=55 
Single center, 
German case series 
2007-2012 
Radiation OR HIFU recurrent disease 
58.2% of patients met 
Mean pre-salvage PSA 9.5 ng/mL 
Median FU 3.0 yrs 
SRP bFFS: 48.7% at 5 yrs 
MFS: 69% at 5 yrs 
CSS: 88.7% at 5 years 
Primary LDR BT and positive nodes correlated with 
worse bFFS 
bFFS was 73.9% for patients within EAU guidelines vs 
11.6% outside EAU guidelines 
 
Sanderson et 
al.20 
2006 
N=51, 33 with 
questionnaire 
Single center 
retrospective case 
series + questionnaire 
1983-2002  
Median Age 65 
Median Pre-SRP PSA 8.0 ng/mL 
 
Some patients received neoadjuvant 
ADT, post op ADT, orchiectomy. 
 
Median FU 7.2 yrs 
SRP PFS: 47% at 5 yrs overall 
Median OS was 12.9 yrs 
PFS was 100%, 80% and 67% for patients with pT2N0, 
preop PSA </=5.0 or Gleason </=7 respectively at 5 yrs. 
Pre-salvage PSA predictive of OS 
 
QOL (median age 72 and median 7.5 years 
after surgery) 
Total continence or occasional dribbling 
reported by 82% with and 69% without AUS 
device 
Overall, 73% characterized overall urinary 
function as “small” “very small” or “no” 
problem.  
Mean sexual function score was clinically 
significantly higher for inflatable penile 
prosthesis (IPP) patients while patients with 
nerve sparing technique did worse than IPP 
patients but better than standard SRP patients 
Ward et al.21 
2005 
N=199 
Single Center, 
retrospective case 
series 
1967-2000 
Life expectancy >/=10 years, all with 
positive prostate biopsy, no metastatic 
disease. 
Median age: 65 years 
Mean Preop PSA 8.5 ng/mL 
Median FU 7.0 yrs 
SRP or salvage 
cystoprostatectomy 
(SCP) 
PFS: 67%, 58%, and 48% at 3, 5, and 10 years. 
CSS: 87%, 79%, and 65% at 3, 5, and 10 years 
Patients undergoing SRP did better than those requiring 
SCP: Median PFS of 8.7 vs 4.4 years.  
Aneuploidy was strongest predictor of PFS 
Pathological stage was strongest predictor of CSS 
 
Intraop rectal injury in 4% of SRP and 10% 
SCP.  
Complete continence maintained in 52% 
Less overall morbidity in surgeries performed 
after 1990 as opposed to before 
Low Dose Rate Brachytherapy (LDR BT) 
Crook et al.26 
2019 
N=92 
Prospective phase II 
study across 20 sites 
in the US and Canada 
2007-2014 
Initial Tx: EBRT alone 
Median age: 70 years 
Positive biopsy >30 months after initial 
tx.  
PSA <10 ng/mL 
Gleason 7 (48%); all others Gleason 2-6 
99Tc bone scan and abdominal/pelvic 
CT showed no regional/distance disease 
Median FU: 4.5 yrs 
LDR BT 
125-I 140 Gy or 
103-Pd 120 Gy 
 Late grade 3 treatment related GI/GU adverse 
events experienced by 14% of patients.  
No late grade 4 or 5 events reported.  
Only V100 (volume receiving 100% of the 
prescribed dose) was predictive of late GI/GU 
adverse events (OR 1.24; p=0.03).  
 
Early grade 3 treatment related GI/GU adverse 
events experienced by 14% of patients.  
No early grade 4 or 5 events reported.  
Half of patients with early grade 3 adverse 
events developed late grade 3 adverse events.  
 
The authors conclude that LDR BT after EBRT 
failure has acceptable tolerance.  
Vargas et al.22 
2014 
N=69 
Single institution 
retrospective case 
series 
1989-2011 
Initial Tx: EBRT alone 
Average Age: 72.5 years 
Positive biopsy more than 2 years after 
initial tx 
PSA >5ng/mL while on HT were 
considered castration resistant prostate 
cancer (CRPC) 
Androgen suppression was used in 89% 
of cases neoadj and adjuvantly  
 
Median FU 5.0 yrs 
LDR BT 
103-Pd 100 Gy 
bFFS: 73.8% in non-castration resistant disease vs 20% in 
castration resistant patients at 5 yrs 
MFS: 90% at 5 yrs 
OS: 64% at 5 yrs 
 
Excluding CRPC patients (n=60) 5 year bFFS was 85.6%, 
74.8%, and 66% for low, intermediate, and high risk 
patients respectively.  
 
5 year bFFS was 77.7% and 43.3% without and with 
treatment delay as defined as receiving 6 months of ADT 
prior to salvage BT 
 
Grado et al.24 
1999 
N=49  
Mayo Clinic 
Scottsdale 
retrospective case 
series 
1990-1996 
Median age: 73.3 
Initial tx: 46 EBRT, 3 BT 
PreSalvage PSA: 5.6 ng/mL (not 
including patients with neoadj ADT or 
prior orchiectomy 
11 patients had already failed additional 
modality and 2 had failed two 
additional modalities. 
One patient had mets while 48 had no 
evidence of mets at time of salvage 
 
Median FU 5.3 yrs 
LDR BT (37 
patients with Pd103 
median 120 Gy and 
12 with I125 
median 160 Gy.)  
 
4 received 
adjunctive radiation 
therapy and 8 
received neoadj 
hormone therapy 
bFFS: 48% at 3 yrs, 34% at 5 yrs 
CSS: 89% at 5 yrs, 79% at 5 yrs 
OS: 75% at 3 yrs, 56% at 5 yrs 
Post-Salv PSA nadir of <0.5 ng/mL associated with 
improved bFFS (RR 4.25 for patients with 0.5 ng/mL or 
more) 
 
 
  
Acute Complications: frequency, urgency, 
hesitancy, nocturia common during first 3 
months but transient and managed with alpha-
blocker 
Sexual Side effects: Only 1 patient reported 
decreased capacity for sexual activity after 
salvBT but 60% of patients were not sexually 
active prior to salvage. 
Burri et al. 25 
2010 
N=37 
Mount Sinai single 
center retrospective 
case series 
1994-2008 
Median age at salvage: 70 
Median PSA at salvage: 5.6 ng/mL 
Initial tx: 32 EBRT, 5 BT 
Median FU 7.2 yrs 
LDR BT (Pd103 
110 Gy, I125 
135Gy) 
bFFS: 65% at 5 yrs, 54% at 10 yrs 
LRFS: 84% at 5 yrs, 76% at 10 yrs 
DMFS: 94% at 5 yrs, 79% at 10 yrs 
CSS: 96% at 5 yrs, 96% at 10 yrs 
OS: 94% at 5 yrs, 74% at 10 yrs 
 
Moman et al.27 
2010 
N=31 
Single center 
Retrospective case 
series 
1994-2009 
Initial Tx: 20 EBRT and 11 125-I 
 
Mean age 69.3 years 
 
Mean pre-Salv PSA 11.4 ng/mL 
With mean doubling time of 13 months 
 
Median FU 9.0 years 
LDR BT 
125-I 145 Gy 
bFFS: 51% at 1  yr, 20% at 5 yrs 
CSS: 74% at 5 yrs, 46% at 10 yrs 
OS: 72% at 5 yrs, 39% at 10 yrs 
 
Gleason >7 had HR 12.4 for BCR compared to Gleason 
≤7 
  
GU Toxicity: 87% and 55% of patients had 
grade 1-2 toxicity in acute (<90 days) and late 
phase (>90 days) respectively. Grade 3 toxicity 
occurred in 19% in late phase  
 
GI Toxicity: 55% and 51% of patients had 
grade 1-2 toxicity in acute and late phase 
respectively. Grade 3 toxicity occurred in 6% in 
late phase. 
Baumann et al.23 
2017 
N=33 
US retrospective case 
series 
1998-2013 
Initial Tx: EBRT 
Median age: 75 years 
Median pre-salvage PSA 5.0 ng/mL 
High risk disease in 55% of patients 
Median FU: 5.1 yrs 
LDR BT 103-Pd 
100 Gy (N=25) or 
HDR BT 30 Gy in 
6 fractions (N=8) 
 
All received 4-6 
months neoadjuvant 
plus adjuvant ADT 
Relapse free survival: 79% at 5 yrs, 67% at 7 yrs 
DMFS: 93% at 5 yrs, 86% at 7 yrs 
OS: 94% at 5 yrs, 85% at 7 yrs 
 
Age at diagnosis, PSA nadir after EBRT, age at 
recurrence, and presalvage PSA were significant 
predictors of relapse free survival after salvage. 
Late grade 3 GU toxicity occurred in 12% of 
patients with resolution or significant 
improvement 3 of 4 of these cases. 
 
1 patient experienced late grade 1 GI toxicity 
but no other cases of GI toxicity were reported. 
 
ADT resulted in grade 2 endocrine toxicity in 
30% of patients.  
High Dose Rate Brachytherapy (HDR BT) 
Chen et al. 28 
2013 
N=52 
Single institution 
retrospective case 
series 
1998-2009 
77% patients had increase in Gleason 
score at recurrence vs primary tx.  
 
Median age: 67.5 
Median PSA 5.0 ng/mL 
 
HDR BT 
36 Gy in 6 fractions 
in 2 separate 
implants performed 
1 week apart 
bFFS: 51% at 5 yrs 
OS: 92% at 5 yrs 
 
No significant predictors of biochemical control 
 
 
GU Toxicity: 2% of patients had grade 3 
toxicity. No grade 4 or 5. 
GI: No grade 3 or higher acute or late GI 
toxicity. Late grade 2 GI in 4% 
Median FU 5.0 yrs 
Yamada et al.29 
2014 
N=42 
Prospective phase II 
study  
2007-2011 
Biopsy proven recurrence after 
definitive EBRT 
 
Median age: 72  
Median presalv PSA: 3.5 ng/mL 
 
 
18 patients had ADT presalvage but all 
discontinued after HDR BT 
 
Excluded: any patient with PSA 
>10ng/mL at assignment and 
international prostate symptom score 
IPSS >15 before salvage therapy. Hx of 
inflammatory bowel disease, prior 
rectal surgery. Abnormal coag studies.  
 
Median FU 3.0 yrs 
HDR BT 
 
192-Ir 32 Gy in 4 
fractions in 1 
implant 
bFFS: 68.5% at 5 yrs 
DMFS: 81.5% at 5 yrs 
OS: 79% at 5 yrs 
 
 
 
GU Toxicity: Acute Grade 1 and Grade 2: 38% 
and 40%. Late Grade 1 and Grade 2: 48% and 
48%. 3 total Grade 3 events but no Grade 4 or 
greater.  
 
GI: Late Grade 1 and Grade 2 GI toxicity 43% 
and 14% without Grade 3 or higher. Most GI 
complications consisted of transient rectal 
bleeding.  
 
Salvage Cryotherapy (SC) 
Pisters et al.30 
1997 
N=150 
MD Anderson 
retrospective case 
series 
1992-1995  
Median age 68.8 years 
91% Caucasian  
Initial Tx:  
-Group 1: RT only (98 EBRT only, 4 
LDR BT only, 8 EBRT and LDR BT.) 
-Group 2: Combination of therapies  
(27 EBRT + HT, 6 EBRT + HT+CT, 1 
EBRT + CT, 4 HT only, 2 HT + CT) 
Mean FU 1.4 yrs 
SC bFFS: 42% overall 
 
Among group 1 patients, BCR was more prevalent in 
patients who received only one freeze-thaw cycle 
compared to two. Also the negative biopsy rate after 
double freeze-thaw cycle was 93% compared to 71% for 
single cycle.  
 
 
Urinary incontinence reported in 73%, 
obstructive symptoms in 67%, impotence in 
72%, and severe perineal pain in 8%. 
Wenske et al. 32 
2013 
N=328 
Columbia University 
NYC retrospective 
case series 
1994-2011 
Median Age 65.8 years 
Median Presalv PSA 4.0 ng/mL 
Median time to SC 67.5 mo after 
primary RT or cryosurgery 
Initial tx: 259 EBRT, 49 LDR BT, 20 
cryosurgery 
 
Median FU 4.0 yrs 
SC bFFS: 63% at 5 yrs, 35% at 10 yrs 
CSS: 91% at 5 yrs, 79% at 10 yrs 
OS: 74% at 5 yrs, 45% at 10 yrs 
 
PSA nadir after SC was predictive of bFFS and CSS.  
 
 
Urethral stricture requiring intervention in 
4.6%, bladder outlet obstruction requiring 
intervention in 3.4%. Rectourethral or 
urethroperineal fistula formation in 1.8%.  
 
55 of the patients underwent focal SC of 
affected lobe. Overall Survival was better for 
this cohort but rectourethral fistula formation 
occurred in 5.5% 
Williams et al.33 
2011 
N=176 of 187 
Canadian 
retrospective case 
series 
1995-2004 
Median age: 70.9 years 
Median presalvage PSA: 4.9 ng/mL 
71% had neoadjuvant ADT for 3-6 
months for downsizing 
Initial tx: 183 EBRT, 3 BT, 1 
EBRT+BT. 
Mean FU 7.5 yrs 
SC DFS (recurrence including BCR): 47%, 39%, and 39% at 
5, 8, 10 yrs 
MFS: 87%, 83%, 82% at 5, 8, 10 yrs 
OS: 95%, 91% and 87% and 5, 8, and 10 yrs 
 
Post salvage nadir >1 had RR 6.63 for recurrence p<0.001 
Presalvage PSA<5ng/mL had DFS 64% at 10 years as 
opposed to 6.7% with PSA>10 ng/mL 
Pres-alvage Gleason and pre-intial tx PSA both also 
correlated with DFS 
 
Perrotte et al.34 
1999 
N=112 of 150 
MD Anderson cross 
sectional study of 
quality of life 
1992-1999 
Median age 68.8 years 
91% Caucasian  
Initial Tx:  
-Group 1: RT only (98 EBRT only, 4 
LDR BT only, 8 EBRT and LDR BT.) 
SC  Incontinence: 72% report dribbling or leakage 
of urine 
 
Voiding Symptoms: Medium to severe 
symptoms in 66% of patients. More cases of 
voiding symptoms without use of urethral 
warming catheter (93% vs 55% of patients) 
-Group 2: Combination of therapies  
(27 EBRT + HT, 6 EBRT + HT+CT, 1 
EBRT + CT, 4 HT only, 2 HT + CT) 
 
Mean FU 1.4 yrs 
 
Sexual Function: 41% of patients were potent 
prior to SC down to 15% after tx. Double 
freeze-thaw cycle group had significantly worse 
potency after tx (8% vs 23%) 
 
Pain: 44% report some degree of chronic 
perineal pain or discomfort. 70% vs 34% had 
pain with vs without urethral warming catheter. 
 
33% overall satisfaction rate with SC 
Ng et al.35 
2007 
N=187 
Canadian 
retrospective case 
series 
1995-2004 
Median age: 70.9 years 
Median presalvage PSA: 4.9 ng/mL 
71% had neoadjuvant ADT for 3-6 
months for downsizing 
Initial tx: 183 EBRT, 3 BT, 1 
EBRT+BT. 
Mean FU 3.3 yrs 
SC  bFFS: 56% in patients with pre-salvage PSA ≤4 ng/mL, 
29% with PSA 4-9.99 ng/mL, and 14% with PSA ≥10 
ng/mL at 5 yrs. 
OS: 97% at 5 yrs, 92% at 8 yrs 
 
 
8% of patients needed additional surgery for 
complications 
High Intensity Focused Ultrasound (HIFU) 
Crouzet et al.38 
2017 
N=418 
International 
retrospective case 
seriers 
1995-2009 
 
Mean time between initial tx and 
salvage: 5.1 years 
Mean age 68.6 years  
Mean pre-salvage PSA 6.8 ng/mL 
191 patients had hx of ADT but none 
continued after HIFU.  
87.1% of patients had one session of 
HIFU while 12.2% and 0.7% had two 
and three session respectively 
Median FU 3.3 yrs 
HIFU bFFS: 49% at 5 yrs overall. 58%, 51%, and 36% for pre-
EBRT low, intermediate, and high risk patients or 67%, 
42%, and 22%, for pre-S-HIFU PSA levels of ≤4, 4-10 
and ≥10 ng/mL respectively.  
MFS: 81% at 7 yrs 
CSS: 82% at 7 yrs 
OS: 72% at 7 yrs 
Lower PSA nadir after S-HIFU correlated with decreased 
need for ADT after salvage. 
 
Gelet et al.39 
2004 
N=71 
Single center French 
retrospective case 
series 
1995-2003 
No staging pre-HIFU 
Median presalv PSA 5.7 ng/mL 
Mean age 67 
 
Mean 1.2 yrs 
HIFU 
 
DFS: 38% at 2.5 yrs 
Negative biopsy rate of 73% at 2.5 yrs 
Metastasis observed in 12.7% overall 
 
 
6% developed urethrorectal fistula 
Kanthabalan et 
al. 40 
2017 
N=150 
UK retrospective 
case series 
2006-2015 
Mean age: 69.8 years 
Mean pre-salvage PSA 5.5 
45.3% with pre-salvage ADT 
Median FU 2.9 yrs 
HIFU 
 
bFFS: 48% at 3 yrs overall. 100%, 61%, and 32% at 3 yrs 
for low intermediate and high risk groups.  
OS: 92% at 5 yrs 
 
Ahmed et al.41 
2012 
N=84 
Two site 
international 
retrospective case 
series 
2004-2009 
Mean age 68.3 
Median Presalv PSA 3.8 ng/mL 
Initial Tx: all EBRT 
Gleason 6-7 only 
 
Median FU 1.7 yrs 
HIFU PFS: 59% at 1 yr, 43% at 2 yrs 
8% of patients did not respond to therapy and had 
increased PSA after therapy  
 
25% of whole cohort and 43% of those biopsied had 
residual disease on biopsy following salvage HIFU 
 
 
Crouzet et al.42 
2012 
N=290 
 
French retrospective 
case series  
1995-2009 
Mean age 68.7 
Mean PSA 6.38 ng/mL 
D’Amico risk group: 19% low risk, 
31.4% intermediate, and 43% high risk 
and undefined in 6.6% 
Mean time from Initial tx to salvage 
was 60 months 
50% received ADT prior to salvage at 
some point 
 
HIFU 
 
PFS: 45%, 31%, and 21% at 5 yrs for low, intermediate, 
and high risk groups 
MFS: 80% at 5 yrs, 79.5% at 7 yrs 
 
Increased risk of progression with higher pre-salvage 
PSA, previous ADT, and Gleason ≥8 vs Gleason ≤6 
 
 
6 cases of urethrorectal fistula, 8 cases of pubic 
bone osteitis. 16% experienced bladder outlet 
obstruction. 
Median FU 2.3 yrs for PFS and 4.0 yrs 
for CSS and MFS 
Stereotactic Body Radiation Therapy (SBRT) 
Fuller et al.44 
2015 
N=29 
Prospective single 
arm study 
2009-2014 
At least 2 years since prior RT 
Median age 73 
Median presalv PSA 3.1 ng/mL 
Median interval between initial tx and 
salvage 88 months 
Initial tx: 27 EBRT, 1 BT, 1 SBRT 
7 on ADT at time of initial failure but 
none received neoadj or adjuvant ADT 
 
Median FU 2.0 yrs 
SBRT 
34 Gy in 5 fractions 
bFFS: 82% at 2 yrs 
 
 
 
GU Toxicity: 18% report ≥grade 2 with one 
case of grade 3 and one case of grade 4.  
 
GI Toxicity: No acute or late GI toxicity greater 
than grade 1 
 
Sexual function: Data available on 10 patients 
who were potent before salvage tx. Three 
patients had a major decrease in potency while 
four had no significant change. (SHIM scoring) 
Leroy et al.45 
2017 
N=23 
Retrospective single 
institution case series 
2011-2014 
Median age 70 yrs 
Initial tx with EBRT or BT +/- ADT 
Median pre-salvage PSA 2.5 ng/mL 
Recurrence at least 2 yr after initial tx 
Median FU 1.9 yrs 
SBRT 
36 Gy in 6 fractions 
DFS: 54% at 2 yrs 
OS: 100% at 2 yrs 
LRFS: 76% at 2 yrs 
Grade 3 toxicity in 9% of patients (cystitis and 
neuralgia) 
Grade 1-2 urinary toxicity was common  
No grade 4 or higher toxicity reported 
Oligometastatic Disease 
Ost et al.46  
2017 
N=62 
Multicenter, 
randomized, phase II 
study 
2012-2015 
Median age 64 (surveillance) and 62 
(MDT) yrs 
Median PSA at inclusion was 3.8 
ng/mL for surveillance and 5.3 for 
MDT 
One metastasis in 29% of surveillance 
group vs 58% of MDT group 
Median FU 3 yrs 
Metastasis directed 
therapy (MDT) 
with SBRT or 
surgery vs 
Surveillance for 
oligometastasis 
Median ADT-free survival was 13 months for surveillance 
group and 21 months for MDT group.  
Local progression in 6 of surveillance group versus none 
of the MDT group. 
PSA decline observed in 35% for surveillance group 
versus 75% in MDT group. 
Grade 1 toxicity in 17% of the MDT patients 
without grade 2 or higher events. 
 
No difference in quality of life between the two 
groups 
Ingrosso et al.47 
2016 
N=40 
Italian retrospective 
case series 
2008-2014 
Median age 74 yrs 
Median Gleason 7 
Primary Tx was surgery, EBRT, or BT 
Median PSA 4.2 ng/mL 
Median FU 2.0 yrs 
SBRT for 
oligometastasis 
bFFS: 44% at 2 yrs 
OS: 95% at last FU 
1 patient with failure within the treatment field 
Grade 2 toxicity in one case (acute phase 
diarrhea) 
 
Grade 3 toxicity in one case (late phase 
dyspepsia) 
Porres et al.48 
2017 
N=87 
German prospective 
study 
2009-2016 
Mean age 66.7 yrs 
Mean pre-salvage PSA 2.63 ng/mL 
Primary Tx was RP in 87.4% +/- 
adjuvant or salvage RT. Primary tx of 
RT in 10.3% of patients. 
Median FU 1.8 yrs 
 
Salvage pelvic 
lymph node 
dissection (sLND) 
Only 69 patients with complete follow up included in 
survival analysis 
bFFS: 35.5% and 27.3% at 1 and 5 yrs 
Systemic therapy-free survival: 63.4% and 35.1% at 1 and 
5 yrs.  
Number of positive lymph nodes and biochemical 
response 6 weeks after surgery were identified as 
predictors of bFFS and ADT-free survival.  
One intraoperative obturator nerve lesion 
 
Postoperative lymphocele occurred in 11.5% of 
cases, half of which required surgical 
intervention. Two patients with obstructive 
ileus also required surgery. 
Karnes et al. 49 
2015 
N=52 
Mayo Clinic 
retrospective case 
series 2009-2013 
Median age 60 yrs 
Median pre-salvage PSA 2.2 ng/mL 
Primary Tx was RP in all cases 
Other therapy after RP in 78.8% of 
cases before sLND 
Median FU 1.7 yrs 
 
Salvage pelvic 
lymph node 
dissection (sLND) 
 
82.7% received 
adjuvant hormone 
therapy 
bFFS: 45.5% at 3 yrs 
MFS: 46.9% at 3 yrs 
CSS: 92.5% at 3 yrs 
 
No further treatment after sLND in 46.2% of patients at 
last follow up.  
 
Androgen Deprivation Therapy (ADT) 
Duchesne et 
al.53 
2016 
N=261 
Randomized Phase 3 
trial 
2004-2012 
Group 1: patients with PSA relapse 
after tx. No more than 12m adj or 
neoadj ADT and ADT must have been 
completed at least 12 m prior to 
randomization. 
Immediate vs 
delayed ADT 
 
Immediate: 
received tx within 8 
Combined: 5 year OS 86.4% in delayed vs 91.2% in 
immediate. Trend toward increased survival in immediate 
with unadjusted HR of 0.55 (95% CI 0.30-1.00; p=0.050) 
 
Group 1 results: 
Delayed arm demonstrated fewer treatment 
associated adverse events than immediate arm.  
 
Did not demonstrate relevant difference in 
quality of life between arms 
 
Group 2: Asymptomatic men unsuitable 
for curative tx because of age, 
comorbidity, or locally advanced 
disease. 
 
Excluded if PSA- doubling time <,3 
months 
 
Median FU 5.0 yrs 
weeks of 
randomization 
 
Delayed: Treatment 
was not to begin 
until at least 2 years 
after randomization 
unless symptoms or 
mets developed, or 
PSA doubling time 
decreased to <6m. 
5 year OS 78.2% vs 84.3% for delayed vs immediate tx 
respectively. The adjusted HR for death was 0.54 in favor 
of immediate tx but not statistically significant (p=0.074). 
 
Statistically significant difference in local progression that 
favored immediate tx but this was not observed with 
distant progression.  
 
41% of men in delayed arm did not reach a trigger (in 
other words they made it the full 2 years before starting 
ADT) 
Crook et al.54 
2012 
N=1,386 
Randomized 
controlled trial 
1999-2005 
Definitive RT >12 m before enrollment 
PSA >3 ng/mL and higher than post-RT 
nadir 
No evidence of mets 
Serum testosterone >5 nmol/L 
Life expectance >5 y 
 
Median FU 6.9 yrs 
Intermittent 
androgen 
deprivation (IAD) 
vs continuous 
androgen 
deprivation (CAD) 
 
IAD: 8 months of 
treatment followed 
by surveillance 
until PSA above 10 
ng/mL 
Median overall survival was 8.8 years in intermittent-
therapy group and 9.1 years in the continuous-therapy 
group.  
 
HR for death with IAD vs CAD was 1.02 (95% CI, 0.86 to 
1.21) which met noninferiority criteria (HR <1.25) with a 
p-value of 0.009 
 
Significant improved outcomes across groups: age <75 yr, 
>3 yr since RT, baseline PSA 3-15 ng/mL, and no prior 
HT. 
  
QOL:  
-Functional domains non-significant trend in 
favor of IAD 
-Symptoms: Hot flashes, desire for sexual 
activity, and urinary symptoms all significantly 
better with IAD (p<0.05) in addition to a trend 
toward improved fatigue (p=0.07).  
 
Potency on IAD: only 29% of those potent at 
baseline recovered potency during non-
treatment interval.  
 
 
Hussain et al.55 
2013 
N=1,535 
Randomized 
controlled trial 
1995-2008 
Prior radiation therapy in 29% and prior 
radical prostatectomy in about 20% of 
patients.  
All patients had metastatic disease  
Median age 70 yrs 
Median pre-ADT PSA: 42 ng/mL 
Patients were randomized after showing 
response to ADT 
 
Intermittent 
androgen 
deprivation (IAD) 
vs continuous 
androgen 
deprivation (CAD) 
 
Patients received 
luteinizing 
hormone-releasing 
hormone agonist 
and anti-androgen 
agent. 
They could not demonstrate statistically significant 
inferiority or non-inferiority of IAD compared to CAD. 
The IAD group experienced more deaths with HR 1.10 but 
90% CI (0.99, 1.23). Median survival after enrollment was 
5.7 yrs for IAD vs 6.4 yrs for CAD 
IAD was associated with better quality of life 
related to impotence (p<0.001), libido (p=0.04), 
and mental health (p=0.003)  
 
At 15 months, 78% of the IAD group had 
resumed hormone therapy. 
Chemotherapy 
James et al. 56 
2016 
N=2962 
RCT 
2005-2013 
Median age 65 yrs 
Prior local therapy in 6% of patients. 
M+ disease in 61%, N+/X M0 in 15%, 
N0M0 in 24%. 
Median FU 3.6 yrs 
Four groups: 
Standard of care 
(SOC) only (HT), 
SOC +zoledronic 
acid (ZA), SOC + 
docetaxel (Doc), 
and SOC + ZA 
+Doc 
Survival advantage identified for SOC + Doc (HR 0.78, 
95% CI 0.66-0.93; p=0.006) and SOC + ZA + Doc (HR 
0.82, 95% CI 0.69-0.97; p=0.022) groups versus the SOC 
alone group 
 
Failure free survival advantage for SOC + Doc (HR 0.61, 
95% CI 0.53-0.70; p=0.413x10-13) and SOC + ZA + Doc 
(HR 0.62, 95% CI 0.54-0.70; 0.134x10-12) 
Grade 3-5 toxicity occurred in 52% of patients 
in both the SOC + Doc and SOC + ZA + Doc 
groups overall.  
 
At 6 months after treatment, Grade 3-5 toxicity 
occurred in 17% for SOC only, 15% for SOC + 
ZA, 36% for SOC + Doc, and 39% for SOC + 
ZA + Doc 
James et al.57 
2017 
N=1917 
RCT 
2011-2014 
Median age 67 yrs 
Median PSA 53 ng/mL 
Median FU 3.3 yrs 
Additional RT in 41% 
Included patients who were newly 
diagnosed and metastatic, high risk 
locally advanced, or relapsed after 
primary surgery or RT. 
ADT alone vs 
combination 
therapy (ADT plus 
abiraterone acetate 
and prednisolone) 
Failure free survival: 75% in combination therapy group 
vs 45% in ADT alone group (HR 0.29; 95% CI, 0.25 to 
0.34; p<0.001) at 3 yrs 
CSS: 76% in combination group vs 82% in ADT alone 
group overall 
 
Any grade 3 or higher adverse event in 47% of 
combination group vs 33% of ADT alone 
group.  
 
Grade 5: 12 events in combination group vs 3 
events in the ADT along group.  
Sweeney et al.58 
2015 
RCT 
2006-2012 
Median age 64 yrs in ADT + Doc group 
and 63 yrs in ADT alone group 
ADT alone vs ADT 
+ Docetaxel (Doc) 
Overall survival benefit for ADT + Doc group over ADT 
alone (HR 0.61; 95% CI 0.47-0.80; p<0.001) 
Grade 3 toxicity occurred in 16.7% of patients. 
Grade 4 toxicity occurred in 12.6% of patients. 
N=790 Median PSA at start of ADT was 50.9 
in ADT + Doc group and 52.1 in ADT 
alone group 
No local therapy in 72.8% in both 
groups. Primary tx of RT or RP in 
others 
Median FU 2.4 yrs 
 
Decrease in PSA level to <0.2 ng/mL occurred in 27.7% 
in the ADT + Doc group and 16.8% in ADT alone group 
(p<0.001).  
 
Median time to castration resistant disease was 20.2 
months for ADT + Doc group vs 11.7 months for ADT 
alone (HR 0.61; 95% CI 0.51-0.72; p<0.001) 
One patient experienced grade 5 toxicity event 
(sudden death).  
 
Most common grade 3-4 events were fatigue, 
neutropenia, and febrile neutropenia.  
McKay et al. 59 
2015 
N=41 
Single arm phase 2 
study 
2008-2010 
 
Median age 58-60 yrs 
Previous tx included RP in 36, 29 of 
whom received salvage RT. The other 5 
patients had primary RT. 
Median FU 2.3 yrs 
 
Docetaxel, 
bevacizumab, 
dexamethasone, 
and ADT 
80% developed PSA progression with median time to 
progression of 27.5 months 
Grade 3 treatment related adverse events in 
39%  
 
Grade 4 treatment related adverse events in 
12% 
Acronym definitions: 
Salvage radical prostatectomy (SRP); external beam radiation therapy (EBRT); low dose rate brachytherapy (LDR BT); high dose rate 
brachytherapy (HDR BT); salvage cryotherapy (SC); high intensity focused ultrasound (HIFU); stereotactic body radiation therapy (SBRT); 
biochemical recurrence (BCR); biochemical failure-free survival (bFFS); cancer specific survival (CSS); progression free survival (PFS); disease 
free survival (DFS); metastasis free survival (MFS); distant metastasis free survival (DMFS); overall survival (OS); prostate specific antigen 
(PSA); androgen deprivation therapy (ADT); hormone therapy (HT); castration resistant prostate cancer (CRPC); lymph nodes (LN); follow up 
(FU); quality of life (QOL) 
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